Umirolimus - Biosensors International

Drug Profile

Umirolimus - Biosensors International

Alternative Names: A9; AXXESS; Ba9; BioFreedom; Biolimus A9 (BA9); Biolimus A9-drug-eluting stent; Biolimus-A-9; BioMatrix; BioMatrix Flex; BioMatrix NeoFlex; BMX-J; Custom NX; Nobori; TRM-986

Latest Information Update: 07 Dec 2017

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Biosensors International Pte Ltd
  • Developer Biosensors International Group; Terumo
  • Class Macrolides
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Coronary artery restenosis

Most Recent Events

  • 13 Dec 2017 Biosensors Europe plans a clinical trial for Coronary artery disease and Myocardial infarction in Spain in 2018 (NCT03365492)
  • 08 Nov 2017 Phase-II clinical trials in Coronary artery restenosis in Switzerland (Intracoronary) (NCT03118895)
  • 11 Sep 2017 Phase-III development for Coronary artery restenosis is ongoing in Canada (Intracoronary) (NCT02843633)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top